cas 142246-63-7, 5'-O-(4,4'-DIMETHOXYTRITYL)-5-FLUORODEOXYURIDINE-3'-(2-CYANOETHYL-N,N-DIISOPROPYL)PHOSPHORAMIDITE

Articles about 142246-63-7Total 8 be found

Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy
Owing to the specific and high binding affinity of aptamers to their targets, aptamer-drug conjugates (ApDCs) have emerged as a promising drug delivery system for targeted cancer therapy. However, in a conventional ApDC, the aptamer segment usually just s
Ma, Yuan,Yang, Jiapei,Zhang, Chuan,Zhu, Lijuan,Zhu, Xinyuan
supporting information
p. 1493 - 1497
(2022/02/10)

ON-DEMAND PHOSPHORAMIDITE SYNTHESIS
The invention relates to a method of synthesis of phosphoramidites by immobilization of a phosphitylation agent on a resin activated to create a charged resin, then putting in contact with the charged resin with a suitable substrate. Phosphoramidites are synthesized in a few minutes from the application of the starting materials. Thus, the process makes it possible to create specific phosphoramidites on demand when they are needed in other applications. The substrates to be applied are mainly nucleosides, thus making it possible to create nucleoside phosphoramidites for the subsequent synthesis of oligonucleotides.
-
Page/Page column 36-38; 48

(2022/01/24)

Enhancing antitumor efficacy of nucleoside analog 5-fluorodeoxyuridine on her2-overexpressing breast cancer by affibody-engineered DNA nanoparticle
Background: Chemotherapy, as an adjuvant treatment strategy for HER2-positive breast cancer, can effectively improve clinical symptoms and overcome the drug resistance of therapeutic monoclonal antibodies. Nucleoside analogues are a class of traditional c
Chen, Shengxi,Du, Jie,Han, Mengnan,Li, Wei,Yang, Xueli,Zhang, Chao,Zhang, Fanghua,Zhang, Honglei
p. 885 - 900
(2020/02/18)

THERAPEUTIC NANOCONJUGATES AND USES THEREOF
The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.
-
Page/Page column 65

(2019/01/30)

Floxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy
Automated attachment of chemotherapeutic drugs to oligonucleotides through phosphoramidite chemistry and DNA synthesis has emerged as a powerful technology in constructing structure-defined and payload-tunable oligonucleotide–drug conjugates. In practice,
Jin, Cheng,Zhang, Hui,Zou, Jianmei,Liu, Yan,Zhang, Lin,Li, Fengjie,Wang, Ruowen,Xuan, Wenjing,Ye, Mao,Tan, Weihong
supporting information
p. 8994 - 8997
(2018/07/25)

DNA Trojan Horses: Self-Assembled Floxuridine-Containing DNA Polyhedra for Cancer Therapy
Based on their structural similarity to natural nucleobases, nucleoside analogue therapeutics were integrated into DNA strands through conventional solid-phase synthesis. By elaborately designing their sequences, floxuridine-integrated DNA strands were sy
Mou, Quanbing,Ma, Yuan,Pan, Gaifang,Xue, Bai,Yan, Deyue,Zhang, Chuan,Zhu, Xinyuan
supporting information
p. 12528 - 12532
(2017/09/12)

Fluorine at the C5 Position of 2′-Deoxyuridine Enhances Repair of a O4-Methyl Adduct by O6-Alkylguanine DNA Alkyltransferases
Alkylation damage at the O6- and O4-atoms of 2′-deoxyguanosine (dG) and thymidine (T), respectively, can be removed by O6-alkylguanine-DNA alkyltransferases (AGTs). Previous studies have shown that human AGT (hAGT) repairs
Sacre, Lauralicia,Wilds, Christopher J.
p. 3003 - 3008
(2017/06/06)

Preparation of oligomeric 2'-deoxy-5-fluorouridylate of defined length and backbone composition: A novel pro-drug form of the potent anti-cancer drug 2'-deoxy-5-fluorouridylate
A recursive protection scheme for FdUMP is employed by synthesizing oligonucleotides consisting of only FdU. 3'-O-exonuclease action releases FdUMP and a shortened oligonucleotide from which further exonuclease action releases more FdUMP. Such oligonucleo
Gmeiner,Sahasrabudhe,Pon,Sonntag,Srinivasan,Iversen
p. 243 - 253
(2007/10/02)